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Introduction: Surgical intervention rates for mesothelioma patients
treated at specialized tertiary hospitals are well more than 42%.
Mesothelioma surgical strategies in the community are less well
defined. This study evaluates the frequency of use and predictors of
cancer-directed surgical intervention in a nontertiary-based popula-
tion and the predictors for surgical intervention.
Methods: The Surveillance, Epidemiology, and End Results data-
base was searched from 1990 to 2004. Variables analyzed included
age, sex, race, year of diagnosis, region, vital status, stage, surgery,
and reasons for no surgery. The association of patient variables on
receipt of cancer-directed surgery was evaluated using 2 tests and
logistic regression. The incidence of mesothelioma was also evalu-
ated over this period of time.
Results: Pathologically proven malignant pleural mesothelioma was
identified in 1166 women and 4771 men. The rate of cancer-directed
surgery was 22% (n  1317). Significant predictors of receiving
cancer-directed surgery included race, age, and stage (all p 
0.0001). A landmark analysis on the effect of cancer-directed sur-
gery on survival after adjusting for patient and disease characteris-
tics demonstrated a hazard ratio of 0.68 (p 0.0001). The incidence
rate of malignant pleural mesothelioma has remained constant.
Conclusions: The rate of surgical intervention in the community is
lower compared with tertiary referral centers. Age, stage, and race
predict the likelihood of receiving cancer-directed surgery. A lower
rate of cancer-directed surgery and worse overall outcome were
observed in black patients. As part of quality assurance, referral of
patients to centers with multidisciplinary programs that include
thoracic surgical expertise should be considered.
Key Words: Malignant pleural mesothelioma, Thoracic surgery,
Surveillance, Epidemiology, and End Results (SEER).
(J Thorac Oncol. 2010;5: 1649–1654)
The role of surgical resection in the management of ma-lignant pleural mesothelioma (MPM) is controversial.
However, phase II and III studies suggest that a multidisci-
plinary approach to mesothelioma, which includes some
combination of chemotherapy, surgery, and/or radiotherapy,
provides the most optimal treatment.1–7 A recent study dem-
onstrated a surgical resection rate of more than 42% at a
tertiary referral center.8 A major criticism of such analyses is
the perception that patients treated at tertiary referral centers
tend to have better performance status and present with
early-stage disease. Therefore, studies from specialty centers
may represent a subset of patients with mesothelioma and are
not representative of most of the patients seen in the rest of
the country.
The Surveillance, Epidemiology, and End Results
(SEER) is a population-based program of the National Cancer
Institute that records cancer incidence, survival, and preva-
lence from specific geographic areas, representing 26% of the
US population.9 This registry would presumably reflect a
more representative cohort of mesothelioma patients than
those solely treated at tertiary referral centers.
The purpose of this study was to investigate the rate at
which surgery was performed in a population-based setting.
In addition, an evaluation of the predictors of surgical inter-
vention and a recent determination of the incidence rate of
MPM in the United States was performed.
METHODS
The SEER database was explored from 1990 to 2004.
We chose only to include cases identified after 1990 because
immunohistochemistry and computed tomography for diag-
nosis and staging of these patients became standard as part of
their evaluation during that interval.
All cases were identified by ICD-O-3 morphology
codes 9050–9055. The SEER 09 registry included cases from
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Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico,
San Francisco-Oakland, Seattle-Puget Sound, and Utah from
1990 to 2004. The SEER 13 registry included cases from
SEER 09 plus Los Angeles, San Jose-Monterrey, Rural Geor-
gia, and Alaska from 1992 to 2004. The SEER 17 registry
included cases from greater California, Kentucky, Louisiana,
and New Jersey from 2000 to 2004.
Only patients with pathologically proven malignant
mesothelioma of pleura and lung were included. Exclusion
criteria included all postmortem cases; any case not con-
firmed microscopically; retroperitoneal, peritoneal, genital,
heart, mediastinum, soft tissue, digestive, other, and unknown
primary site.
SEER staging consensus guidelines for MPM encom-
pass three major categories to classify tumor location and
metastases.
Early: Invasive tumor confined to pleura ipsilateral
parietal and/or visceral pleura; mesothelioma with nodules
beneath the visceral pleural surface; and localized, not oth-
erwise specified. Late: Adjacent connective tissue, pericar-
dium, endothoracic fascia, diaphragm; mesothelioma nodules
that have broken through the visceral pleural surface to the
lung surface, lung involvement not otherwise specified; ex-
tension to adjacent organs such as the chest wall, ribs, heart
muscle, mediastinal organs and tissues; mesothelioma with
malignant pleural fluid/effusion; and regional lymph nodes.
Distant: Contralateral pleura and lung, extension to intra-
abdominal organs, cervical tissues, peritoneum, metastasis;
unknown if extension or metastasis; and distant lymph nodes.
Variables analyzed included age, sex, race, year of
diagnosis, laterality, vital status, region, stage, surgery, and
reasons for no surgery. The association of patient and disease
factors on receipt of cancer-directed surgery was evaluated
using 2 tests for categorical variables and logistic regression
for continuous variables and multivariate analysis. Overall
survival was defined as the time between the initial diagnosis
date and either date of death or last follow-up. The associa-
tion of patient and disease factors on overall survival was
estimated by the Kaplan-Meier method and evaluated using
the log-rank test for categorical variables and Cox propor-
tional hazards model for continuous variables and multivar-
iate analysis. A landmark analysis at 2 months was performed
to evaluate the effect of cancer-directed surgery on survival
after adjusting for patient and disease characteristics. All
computations were done using SAS, version 9.1.
RESULTS
From 1990 to 2004, 5937 pathologically proven cases
of MPM were identified from the SEER database. Patient
characteristics are outlined in Table 1.
The number of patients who underwent cancer-directed
surgery was 1317 (22%). Of these patients, 486 (37%) had
partial removal of primary cancer site; 279 (21%) local tumor
excision; 237 (18%) radical surgery; 129 (10%) total removal
of primary cancer site; 54 (4%) debulking; 54 (4%) surgery
unspecified; 24 (2%) local tumor destruction; 27 (2%) sur-
gery of regional or distant site; 16 (1%) resection less than
a lobe; 8 (1%) lobectomy; and 3 (1%) pneumonectomy.
Of the 4587 patients who did not undergo surgery, 3383
(57%) did not have surgery recommended, surgery was
contraindicated in 200 (3%), 65 patients refused surgery
(1%), and 2 patients died before planned surgical interven-
tion. The reason for not undergoing surgery was unknown in
937 patients (16%).
Both univariate and multivariate analyses of predictors
on cancer-directed surgery showed that race, age, stage,
diagnosis year, and receiving radiation were significantly
associated with cancer-directed surgery (Table 2). Younger
patients were more likely to receive cancer-directed surgery
(p  0.0001). Black patients were less likely to have cancer-
directed surgery compared with white patients (odds ratio:
0.45, 95% confidence interval: 0.31–0.64). Patients with late
stage or distant disease were less likely to receive cancer-
directed surgery than patients with early-stage disease (p 
0.0001). Patients diagnosed more recently were more likely
to receive cancer-directed surgery (p  0.0001).
Of the 5937 patients, 804 (14%) were alive at the time
of last follow-up. Median overall survival was 8 months
TABLE 1. Patient, Disease, and Treatment Characteristics
(n  5937)
Variable Categories Total
Registry SEER 9 3245 (55%)
SEER 13 (1992) 966 (16%)
SEER 17 (2000) 1726 (29%)
Sex Male 4771 (80%)
Female 1166 (20%)
Race White 5433 (92%)
Black 294 (5%)
Other 199 (3%)
Unknown 11 (1%)
Age (yr) 15–49 277 (5%)
50–59 675 (11%)
60–69 1366 (23%)
70–79 2281 (38%)
80 1337 (23%)
Unknown 1 (1%)
Diagnosis year 1990–1994 1270 (21%)
1995–1999 1462 (25%)
2000–2004 3205 (54%)
Overall stage Early 633 (11%)
Late 3791 (64%)
Distant 952 (16%)
Unknown 561 (9%)
Cancer-directed surgery No 4587 (77%)
Yes 1317 (22%)
Unknown 33 (1%)
Radiation No 4994 (84%)
Yes 835 (14%)
Unknown 108 (2%)
Vital status Alive 804 (14%)
Dead 5133 (86%)
Survival in months Median (95% CI) 8 (7–8)
SEER, Surveillance, Epidemiology, and End Results; CI, confidence interval.
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(95% confidence interval: 7–8 months). Stage, sex, age, and
race were all independently associated with overall survival
(Table 3). Kaplan-Meier survival curves demonstrate which
cohorts had improved survival: females versus males (Fig-
ure 1), early stage versus later stages (Figure 2), and white
versus black patients (Figure 3).
Because date of surgery is not captured in SEER, a
landmark analysis was performed to try to minimize the
lead-time bias that invariably favors patients treated by sur-
gical intervention when compared with patients without sur-
gery. We estimated that cancer-directed surgery would be
performed within 2 months of the diagnosis date. Therefore,
the landmark analysis starts 2 months after the diagnosis date
to examine the effect of surgery after adjusting for patient and
disease characteristics (Figure 4). There were 923 patients
who died before this 2-month landmark. A Cox proportional
hazards model demonstrated significantly improved survival
for patients receiving cancer-directed surgery (hazard ratio: FIGURE 1. Survival by gender.
TABLE 2. Variables Associated with Receiving Cancer Directed Surgery
Variable Category N
Frequency Receiving
Cancer-Directed Surgery (%)
Univariate
p Value
Multivariate
p Value
Adjusted OR
(95% CI)
Sex Female 1160 257 (22%) 0.89 0.24 1
Male 4744 1060 (22%) 1.11 (0.93–1.31)
Race White 5404 1233 (23%) 0.003 0.0001 1
Black 292 42 (14%) 0.45 (0.32–0.65)
Other 198 41 (21%) 0.77 (0.53–1.11)
Age Per 5-yr increase in age — — 0.0001 0.0001 0.84 (0.81–0.86)
Stage Early 628 159 (25%) 0.0001 0.0001 1
Late 3772 938 (25%) 0.92 (0.75–1.13)
Distant 951 166 (17%) 0.52 (0.40–0.67)
Diagnosis year 1990–1994 1268 277 (22%) 0.05 0.001 1
1995–1999 1456 295 (20%) 0.97 (0.80–1.19)
2000–2004 3180 745 (23%) 1.27 (1.07–1.52)
Radiation No 4970 959 (19%) 0.0001 0.0001 1
Yes 835 321 (38%) 2.51 (2.12–2.97)
OR, odds ratio; CI, confidence interval.
TABLE 3. Effect of Patient and Disease Variables on Survival (Not Including Treatment Variables)
Variable Category
1-yr Survival
(95% CI)
5-yr Survival
(95% CI)
Univariate
p Value
Multivariate
p Value
Adjusted HR
(95% CI)
Stage Early 0.44 (0.40–0.49) 0.11 (0.07–0.14) 0.0001 0.0001 1
Late 0.39 (0.38–0.41) 0.05 (0.04–0.06) 1.17 (1.06–1.30)
Distant 0.25 (0.25–0.28) 0.03 (0.02–0.05) 1.70 (1.51–1.91)
Sex Female 0.41 (0.38–0.44) 0.10 (0.08–0.12) 0.0001 0.0001 1
Male 0.36 (0.35–0.37) 0.04 (0.03–0.05) 1.21 (1.12–1.30)
Age Per 5-yr increase in age — — 0.0001 0.0001 1.12 (1.11–1.14)
Race White 0.37 (0.36–0.39) 0.05 (0.04–0.05) 0.05 0.0002 1
Black 0.31 (0.26–0.37) 0.07 (0.04–0.11) 1.29 (1.13–1.47)
Other 0.30 (0.23–0.37) 0.05 (0.02–0.10) 1.18 (1.00–1.38)
Diagnosis year 1990–1994 0.36 (0.34–0.39) 0.05 (0.04–0.06) 0.60 —
1995–1999 0.35 (0.33–0.38) 0.05 (0.04–0.07)
2000–2004 0.38 (0.36–0.40) 0.03 (0.02–0.05)
CI, confidence interval.
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0.68, 95% confidence interval: 0.63–0.74) when controlling
for age, stage, race, and gender (Table 4).
When we examined the relationship between race and
stage, we found stage distribution among white patients to be
529 (12%) early stage, 3484 (71%) late stage, and 845 (17%)
distant stage. Of the black patients, 32 (12%) were early
stage, 176 (64%) late stage, and 67 (24%) distant stage. Of
the remaining patients, 22(12%) were early stage, 125 (68%)
late stage, and 38 (21%) distant stage. A significantly greater
number of black patients presented with more advanced stage
than white patients (p  0.009).
The incidence of pleural mesothelioma has not changed
substantially over the 15-year time period of this study. The
incidence rates shown in Table 5 are per 100,000 and age
adjusted to the 2000 US standard population. Approximately
3300 new cases of pleural mesothelioma occur per year.
FIGURE 2. Survival by stage.
FIGURE 3. Survival by race.
FIGURE 4. Survival by cancer-directed surgery using land-
mark of 2 months after diagnosis.
TABLE 4. Landmark Analysis of the Effect of Cancer-
Directed Surgery on Survival After Adjusting for Patient and
Disease Characteristics
Variable Category
Multivariate
p value
Adjusted HR
(95% CI)
Cancer-directed
surgery
No 0.0001 1
Yes 0.68 (0.63–0.74)
Stage Early 0.0001 1
Late 1.20 (1.07–1.35)
Distant 1.59 (1.39–1.82)
Sex Female 0.0001 1
Male 1.26 (1.17–1.37)
Age Per 5-yr increase in age 0.0001 1.09 (1.08–1.11)
Race White 0.13 1
Black 1.15 (0.99–1.34)
Other 1.09 (0.91–1.31)
The landmark analysis starts at 2 mo after diagnosis date to look at the effect of
surgery after adjusting for patient and disease characteristics. There were 923 patients
who died before 2 mo.
CI, confidence interval.
TABLE 5. Incidence of Malignant Pleural Mesothelioma
(per 100,000)
Year Rate Count Population
1990 1.1 243 23,657,474
1991 1.1 244 23,998,620
1992 1.2 272 24,368,037
1993 1.1 240 24,713,120
1994 1.2 265 25,022,087
1995 1.2 271 25,339,972
1996 1.1 270 25,652,964
1997 1 242 25,969,420
1998 1.1 266 26,263,552
1999 1.1 276 26,520,657
2000 1.1 269 26,791,232
2001 1.1 269 27,069,511
2002 1 263 27,272,019
2003 0.9 245 27,477,089
2004 1.1 282 27,672,787
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DISCUSSION
The overall treatment of MPM is controversial but has
evolved considerably during the past several decades. Ad-
vances in the management of MPM include easier and more
accurate methods of pathologic diagnosis, a better under-
standing of the natural history of the disease, improved methods
of staging and of selecting patients for surgery, a significant
decrease in operative mortality especially for extrapleural pneu-
monectomy (EPP), improvements in local control with com-
bined resection and radiotherapy, better systemic therapies,
and emerging insights into tumor biology.1–7,10,11,12 Despite
these advances, 5-year overall survival has remained approx-
imately 15%.10,11
Surgical opinions are widely disparate.10,13,14 Propo-
nents of EPP believe that it frequently allows a more com-
plete removal of all gross tumor and facilitates the adminis-
tration of postoperative high-dose hemithoracic radiation.6
Proponents of pleurectomy/decortication believe that it pro-
vides adequate cytoreduction, especially for patients with
early-stage tumors, is associated with a lower morbidity and
mortality than EPP and preserves lung function for a tumor
that will invariably recur.12 Resection also provides palliation
of an entrapped lung, ventilation/perfusion mismatch, pneu-
monia, and chest pain. Talc pleurodesis is a palliative proce-
dure to control the pleural effusion. Moreover, Boutin et al.13
demonstrated an encouraging median survival of 36 months
for patients with stage IA mesothelioma treated by talc
pleurodesis alone. Even opponents of surgical resection ac-
knowledge the benefit of talc pleurodesis in this setting.14
Therefore, regardless of personal bias, it appears that an
evaluation by a thoracic surgeon in a multidisciplinary con-
text should be considered for the optimal management of
pleural mesothelioma.
Two noteworthy publications have explored the SEER
database in mesothelioma. Spiritas et al.15 published their
study in 1988 before the routine use of immunohistochemis-
try, electron microscopy, and computed tomography. The
population in that report may not have represented an accu-
rately diagnosed group of mesothelioma patients, leading to
skewed survival results.11 Misdiagnosis is a well-known con-
founder of survival in mesothelioma, and a variety of studies
have found as many as 3 in 15 women and 1 in 20 men with
a misdiagnosis of pleural mesothelioma.16 Price et al.17 ex-
plored the SEER database in 2004 and found an incidence
trend of approximately 3000 cases/y, which is similar to our
finding of 3300 cases/y. However, these authors did not
provide treatment, staging, and survival data.
Predictors of receiving cancer-directed surgical treat-
ment included younger age, earlier stage, and white race.
Interestingly, gender did not play a role in predicting the
receipt of cancer-directed surgery but was highly significant
in predicting outcome irrespective of treatment.
An improvement in survival was observed for patients
undergoing cancer-directed surgery when controlling for age,
stage, gender, and treatment. However, the specifics of the
surgical procedure performed are unclear in the SEER cod-
ing. In addition, the number of SEER patients receiving
treatment at tertiary referral centers is unknown, but given the
small number of pneumonectomies recorded (n  3), which
is the most common resection performed for this disease, it is
unlikely that a large number of patients were treated outside
of the community.
The role of black race, in addition to age and stage, as
a poor prognostic factor is a new but not unexpected finding
that parallels racial disparities observed in other malignan-
cies.18 Factors such as presentation at later stages and less
access to medical care are likely to contribute to these
observed disparities. Younger white patients with early-stage
disease are more likely to undergo cancer-directed surgery for
mesothelioma.
The major strength of this study is in providing infor-
mation on a representative subset of most of patients cur-
rently suffering from mesothelioma in the United States.
Limitations of this study include selection and lead-time bias
in favor of surgically treated patients, despite controlling for
a 2-month lead-time bias in the landmark analysis, lack of
chemotherapy, detailed radiotherapy and surgical data, and
the lack of stratification by histologic subtype. The observa-
tional nature of this study does not allow one to determine
superiority of one treatment over another. Prospective ran-
domized trials have been attempted in Europe to answer the
question of optimal management but have been slow to
accrue patients.
In summary, this study demonstrates a lower rate of
surgical intervention in the majority of patients with mesothe-
lioma in the community when compared with tertiary referral
centers. Younger patients with early-stage disease undergo
surgical intervention more frequently. Surgical intervention
rates and overall outcome were lower in black patients. The
role of surgical resection, especially EPP, is controversial, but
the benefits of symptomatic palliation are well accepted. To
ensure quality control, it is recommended that patients with
pleural mesothelioma be evaluated by a multidisciplinary
team including thoracic surgical consultation.
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